The Latin America, Middle East and Africa Digital Dose Inhaler Market would witness market growth of 23.2% CAGR during the forecast period (2023-2030).
Inhalers also go by the name’s allergy spray and pump. Inhalers are typically used to treat and administer medication for respiratory diseases, such as chronic obstructive pulmonary disease and asthma. Patients with obstructive airway disease (OAD) rely heavily on inhalers for treatment. Inhalers reduce the amount of medication in the pharynx or mouth and the need for precise synchronization with device activation. The digital inhaler is a self-administered device that delivers a specific dose of medication to the airways as a brief burst of aerosolized medication. According to the release and dosage management, the digital inhaler has sensors that detect usage and measure inspiratory flow. Metered dose inhalers (MDI) and dry powder inhalers (DPI) are two of the digital dose inhaler varieties available on the market.
The increase in the incidence of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), asthma, and respiratory allergies, among others, and a growing mortality rate because of the respective diseases and disorders are among the main drivers promoting the market. Inhalation therapy devices such as metered dose inhalers with internet connectivity, e-dose counters, and compact inhalers, among others, are among the inhalation therapy devices whose technological advancements are accelerating market growth.
Asthma is among the Department of Health's (DoH) main public health priorities. The Asthma program of the Department of Health aims to reduce emergency department visits, hospitalizations, work and school absences, and, most importantly, asthma-related fatalities. This can be accomplished by improving asthma treatment and diagnosis in primary care settings. The government's guidelines aim to enhance the diagnosis and management of adult asthma by primary care physicians, thereby preventing asthma-related premature fatalities. The increasing prevalence of asthma and the continued research into its treatment will increase the use of digital dosage inhalers. Consequently, it is anticipated that the market will expand in the region.
The Brazil market dominated the LAMEA Digital Dose Inhaler Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $821 million by 2030. The Argentina market is showcasing a CAGR of 23.9% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 22.9% during (2023 - 2030).
Based on Product, the market is segmented into Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI). Based on Type, the market is segmented into Branded Medication, and Generic Medication. Based on Indication, the market is segmented into COPD, Asthma, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Digital Dose Inhaler Market is Projected to reach USD 49 Billion by 2030, at a CAGR of 19.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
By Product
By Type
By Indication
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
